FDA Asks ODAC To Ponder Shift Away From Single-Arm Studies
This article was originally published in The Pink Sheet Daily
Executive Summary
At its Feb. 8 meeting on issues surrounding confirmatory post-marketing studies, the Oncologic Drugs Advisory Committee will discuss whether and when randomized studies should be required to secure accelerated approval.
You may also be interested in...
Farydak Confirmatory Trial To Come Years After Accelerated Approval
Despite the agency’s preference that confirmatory trials generally be under way at the time of accelerated approval, Novartis’ panobinostat Phase III trial isn’t expected to begin for approximately three years.
Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval
Data from the pivotal Phase I trial studying crizotinib in NSCLC patients demonstrates significant increase in one- and two-year survival against historical controls.
Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval
Data from the pivotal Phase I trial studying crizotinib in NSCLC patients demonstrates significant increase in one- and two-year survival against historical controls.